Affordable Access

deepdyve-link
Publisher Website

Evaluation of the efficacy and safety of Tribulus terrestris in male sexual dysfunction-A prospective, randomized, double-blind, placebo-controlled clinical trial.

Authors
  • Kamenov, Zdravko1
  • Fileva, Svetlana2
  • Kalinov, Krassimir3
  • Jannini, Emmanuele A4
  • 1 Clinic of Endocrinology, Alexandrovska University Hospital, Medical University-Sofia, 1, Georgi Sofiiski Str 1431, Sofia, Bulgaria. Electronic address: [email protected]
  • 2 Medical and Regulatory Affairs Department, Sopharma AD, Sofia, Bulgaria.
  • 3 Department of Informatics, New Bulgarian University, Sofia, Bulgaria.
  • 4 Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy.
Type
Published Article
Journal
Maturitas
Publication Date
May 2017
Volume
99
Pages
20–26
Identifiers
DOI: 10.1016/j.maturitas.2017.01.011
PMID: 28364864
Source
Medline
Keywords
License
Unknown

Abstract

86 patients in each group completed the study. The IIEF score improved significantly in the TT group compared with the placebo group (Р<0.0001). For intention-to-treat (ITT) there was a statistically significant difference in change from baseline of IIEF scores. The difference between TT and placebo was 2.70 (95% CI 1.40, 4.01) for the ITT population. A statistically significant difference between TT and placebo was found for Intercourse Satisfaction (p=0.0005), Orgasmic Function (p=0.0325), Sexual Desire (p=0.0038), Overall Satisfaction (p=0.0028) as well as in GEQ responses (p<0.0001), in favour of TT. There were no differences in the incidence of adverse events (AEs) between the two groups and the therapy was well tolerated. There were no drug-related serious AEs. Following the 12-week treatment period, significant improvement in sexual function was observed with TT compared with placebo in men with mild to moderate ED. TT was generally well tolerated for the treatment of ED.

Report this publication

Statistics

Seen <100 times